Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 9, 1999, Pages 775-782

  Wu, Marietta ^a   Gunning, William ^a   Ratnam, Manohar ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Dept of Biochem and Molec Biology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; RECEPTOR PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL TYPE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MALIGNANT TRANSFORMATION; OVARY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; UTERINE CERVIX; UTERUS;

CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CERVIX UTERI; DOWN-REGULATION; FEMALE; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; GENITAL NEOPLASMS, FEMALE; HUMANS; IN SITU HYBRIDIZATION; OVARIAN NEOPLASMS; OVARY; RECEPTORS, CELL SURFACE; RNA PROBES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS; UTERUS;

EID: 0032883172     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lacey, S. W., Sanders, J. M., Rothberg, K. G., Anderson, R. G., and Kamen, B. A. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J. Clin. Invest., 84: 715-720, 1989.
2. Ratnam, M., Marquardt, H., Duhring, J. L., and Freisheim, J. H. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry, 28: 8249-8254, 1989.
3. Shen, F., Wang, H., Zheng, X., and Ratnam, M. Expression levels of functional folate receptors-α and -β are related to the number of N-glycosylated sites. Biochem. J., 327: 759-764, 1997.
4. Shen, F., Wu, M., Ross, J. F., Miller, D., and Ratnam, M. Folate receptor type γ is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry, 34: 5660-5665, 1995.
5. Yan, W., and Ratnam, M. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the Hydrophobic portion of the signal. Biochemistry, 34: 14594-14600, 1995.
6. Ross, J. F., Chaudhuri, P. K., and Ratnam. M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer (Phila.), 73: 2432-2443, 1994.
7. Ross, J. F., Wang, H. W., Behm, F. G., Mathew, P., Booth, R., and Ratnam, M. Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer (Phila.), 85: 348-357, 1999.
8. Mazzoni, A., Mezzanzanica, D., Jung, G., Wolf, H., Colnaghi, M. I., and Canevari, S. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res., 56: 5443-5449, 1996.
9. Mezzanzanica, D., Garrido, M. A., Neblock, D. S., Daddona, P. E., Andrew, S. M., Zurawski, J., Segal, D. M., and Wunderlich, J. R. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res., 51: 5716-5721, 1991.
10. Mezzanzanica, D., Canevari, S., and Colnaghi, M. I. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int. J. Clin. Lab. Res., 21: 159-164, 1991.
11. Canevari, S., Mezzanzanica, D., Mazzoni, A., Negri, D. R., Ramakrishna, V., Bolhuis, R. L., Colnaghi, M. I., and Bolis, G. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J. Hematother., 4: 423-427, 1995.
12. Canevari, S., Mezzanzanica, D., Mazzoni, A., Negri, D. R., Figini, M., Ramakrishna, V., Bolis, G., and Colnaghi, M. I. Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunol. Immunother., 45: 187-189, 1997.
13. Luiten, R. M., Warnaar, S. O., Sanborn, D., Lamers, C. H., Bolhuis, R. L., Litninov, S. V., Kurawski, V. R., Jr., and Coney, L. R. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (Mov 18) and displays decreased immunogenicity in patients. J. Immunother., 20: 496-504, 1997.
14. Melani, C., Figini, M., Nicosia, D., Luison, E., Ramakrishna, V., Casorati, G., Parmiani, G., Eshhar, Z., Canevari, S., and Colombo, M. P. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain FR of antifolate receptor antibody. Cancer Res., 58: 4146-4154, 1998.
15. Roy, E. J., Cho, B. K., Rund, L. A., Patrick, T. A., and Kranz, D. M Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int. J. Cancer, 76: 761-766, 1998.
16. Turek, J. J., Leamon, C. P., and Low, P. S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell Sci., 106: 423-430, 1993.
17. Leamon, C. P., and Low, P. S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA, 88: 5572-5576, 1991.
18. Leamon, C. P., and Low, P. S. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem., 267: 24966-24971, 1992.
19. Leamon, C. P., Pastan, I., and Low, P. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. J. Biol. Chem., 268: 24847-24854, 1993.
20. Leamon, C. P, and Low, P. S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Targeting, 2: 101-112, 1994.
21. Ladino, C. A., Chari, R. V., Bourret, L. A., Kedersha, N. L., and Goldmacher, V. S. Folate-maytansinoids. Target-selective drugs of low molecular weight. Int. J. Cancer, 73: 859-864, 1997.
22. Mathias, C. J., Wang, S., Lee, R. J. Waters, D. J., Low, P. S., and Green, M. A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med., 37: 1103-1008, 1996.
23. Mathias, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., and Green, M. A. Indium-111/-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med., 39: 1579-1585, 1998.
24. Mathias, C. J., and Green, M. A. A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl. Med. Biol., 25: 585-587, 1998.
25. Wang, S., Luo, J., Lantrip, D. A., Waters, D. J., Mathias, C. J., Green, M. A., Fuchs, P. C., and Low, P. S. Design and synthesis of [111 In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconj. Chem., 8: 673-679, 1997.
26. Lee, R. J., and Low, P. S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem., 269: 3198-3204, 1994.
27. Lee, R. J., and Low, P. S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233: 134-144, 1995.
28. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol., 14: 1574-1578, 1996.
29. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier-and receptor-mediated transport of folate antagonist targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol., 48: 459-471, 1995.
30. Mantovani, L. T., Miotti, S., Menard, S., Canevari, S., Raspagliesi, F., Bottini, C., Bottero, F., and Colnaghi, M. I. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur. J. Cancer, 30A: 363-369, 1994.
31. Veggian, R., Fasolato, S., Menard, S., Minucci, D., Pizzetti, P., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori, 75: 510-513, 1989.
32. Stein, R., Goldenberg, D. M., and Mattes, M. J. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int. J. Cancer, 47: 163-169, 1991.
33. Boerman, O. C., Van Niekerk, C. C., Makkink, K., Hanselaar, T. G. J. M., Kenemans, P., and Poels, L. G. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int. J. Gynecol. Pathol., 10: 15-25, 1991.
34. Buist, M. R., Molthoff, C. F. M., Kenemans, P., and Meijer, C. J. L. M. Distribution of OV-TL3 and MOv18 in normal and malignant ovarian tissue. J. Clin. Pathol., 48: 631-638, 1995.
35. Garin-Chesa, P., Campbell, I., Saigo, P. E., Lewis, J. L., Old, L. J., and Rettig, W. J. Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folale-binding protein. Am. J. Pathol., 142: 557-567, 1993.
36. Toffoli, G., Cernigo, C., Russo, A., Galls, A., Bagnoli, M., and Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer, 74: 193-198, 1997.
37. Miotti, S., Canevari, S., Menard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39: 297-303, 1987.
38. Weitman, S. D., Lark, R. H., Coney, L. R., Fort, D. W., Frasca, V., Vincent, R., Zurawski, J., and Kamen, B. A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res., 52: 3396-3401, 1992.
39. Weitman, S. D., Weinberg, A. G., Coney, L. R., Zurawski, V. R., Jennings, D. S., and Kamen, B. A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res., 52: 6708-6711, 1992.
40. Orr, R. B., Kreisler, A. R., and Kamen, B. A. Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers. J. Natl. Cancer Inst., 87: 299-303, 1995.